Do GLP-1s Curb Nicotine Cravings?
The nicotine question echoes the alcohol one — a plausible mechanism and real interest, but the direct trial evidence is thinner than the headlines suggest.
The short answer
It is an open question. People taking GLP-1 medications sometimes report less pull toward cigarettes, and the biology that makes researchers curious about alcohol applies to nicotine too. But the strongest trials running now are mostly designed to study weight gain after quitting, not whether the drugs help people quit in the first place. Treat "GLP-1s help you stop smoking" as a hypothesis being tested, not an established finding.
What is actually being studied
Much of the current randomized work pairs semaglutide with standard cessation support and measures body weight. One double-blind trial randomized 177 treatment-seeking smokers with overweight or obesity to semaglutide or placebo, with everyone receiving nicotine patches and brief counseling; its primary outcome is body-weight change, with smoking abstinence as an exploratory measure. That design tells you the field's near-term priority is the well-known problem of post-quit weight gain — a real barrier to quitting — more than a claim that the drug itself extinguishes nicotine craving.
Why the mechanism is plausible
GLP-1 receptors sit within the brain's reward circuitry, not only the gut. That overlap is why a medication developed for blood sugar and appetite is being examined across several reward-driven behaviors at once. Plausibility is a reason to study something carefully; it is not evidence of a treatment effect in people. The alcohol literature is a useful caution here: even there, the best trial showed some drinking measures moved while others did not.
What this means now
No one should start, stop, or switch a GLP-1 medication to quit smoking based on current evidence. People who want to stop smoking have access to treatments with strong evidence today — nicotine replacement, varenicline, and counseling — and those should not be deferred while this research matures. If a clearer signal emerges from trials designed to measure cessation directly, we will update this brief.
Citations
- Williams et al. Once-weekly semaglutide for limiting post-smoking-cessation weight gain: study protocol (randomized controlled trial). PubMed (2025).
- GLP-1 receptor agonists for smoking cessation: a narrative review of weight-management potential. PMC (2026).